Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of SchizophreniaOlean Times Herald6 days ago
MARLBOROUGH, Mass. & PARAMUS, N.J.--(BUSINESS WIRE)--Dec 13, 2018--Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that positive results from SEP 361-201, a pivotal Phase 2 study that evaluated
- Other OTC
Sumitomo Dainippon Pharma Co. and Sunovion Pharmaceuticals Inc. own U.S. Patent No. 5,532,372. The ’372 patent relates generally to “novel imide compounds and their acid addition salts” that are useful as antipsychotic agents. ’372 patent col. 1 ll. 8–12.
Befitting Sumitomo Dainippon Pharma’s tenth anniversary of the merger, “Innovation today, healthier tomorrows” is the global slogan adopted by four pharmaceutical companies of Sumitomo Dainippon Pharma group (Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Boston Biomedical, and Sumitomo Pharmaceuticals (Suzhou)).
Sumitomo Dainippon Pharma Co., Ltd. engages in manufacturing, sale, import and export of pharmaceuticals products. It operates through the Pharmaceutical Business and Other Business segments.
The following slide deck was published by SUMITOMO DAINIPPON PHARMA CO LTD ADR in conjunction with their 2018 Q1 earnings call.
Sumitomo Dainippon Pharma Co. v. Emcure Pharmaceuticals Ltd. No Need to Resolve Full Claim Scope Upon Determining Coverage Over Dispositive Compound Fed Cir affirms stipulated judgment of infringement in Hatch-Waxman case.
SUMITOMO DAINIPPON PHARMA CO. v. EMCURE PHARM. LTD. 3 . active pharmaceutical ingredient in each party’s commer-cial product, we need not determine what else falls within the claim’s ambit to resolve thepresent dispute. We affirm. I . Stereochemistry is the study of a molecule’s three-dimensional structure. Stereoisomers are molecules with